Hybrid expert panel meeting Renal cell carcinoma: Updates on treatment and management


1. What factors currently drive your treatment choices in RCC? (Please rank according to the importance of treatment decision making)
1st2nd3rd4th5th
1st
2nd
3rd
4th
5th
1st2nd3rd4th5th
1st
2nd
3rd
4th
5th
2. What proportion of your RCC patients receive the below regimens as first-line systemic therapy? (Please input a numerical % value)
3. What proportion of your RCC patients are eligible for second-line systemic therapy? (Please input a numerical % value)
4. What proportion of your patients with RCC receive the below therapies in the second-line setting? (Please input a numerical % value)
5. What proportion of your RCC patients are eligible for third-line systemic therapy? (Please input a numerical % value)
6. Which adverse events of cabozantinib do you find most challenging? (You may select more than one)